<DOC>
	<DOCNO>NCT00644553</DOCNO>
	<brief_summary>To compare safety/tolerability efficacy 14-day course clarithromycin extended-release tablet ( 2 x 500 mg QD ) 14-day course amoxicillin-clavulanate tablet ( 875/125 mg BID ) treatment ambulatory subject Acute Bacterial Sinusitis ( ABS ) .</brief_summary>
	<brief_title>Comparative Study Safety Efficacy Clarithromycin Extended-Release Tablets Versus Amoxicillin-Clavulanate Treatment Acute Bacterial Sinusitis</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>The female must nonlactating risk pregnancy . Subject must diagnosis ABS . The diagnosis must base following : A sinus radiograph ( Water 's view ) CT scan evidence maxillary opacification Air/fluid level purulent discharge nose At least two follow additional sign symptom last longer seven day prior longer 28 day Evaluation 1 . A pretreatment sample sinus puncture Middle meatus endoscopy must obtain bacterial aerobic culture Susceptibility testing ( applicable select investigative site ) . Subject must suitable candidate oral antibiotic therapy able swallow tablet intact . A medical history hypersensitivity allergic reaction clarithromycin , erythromycin , amoxicillin/clavulanate , penicillin macrolide antibiotic . History amoxicillinclavulanate associate cholestatic jaundicehepatic dysfunction . Females pregnant lactating . Subject either following : Chronic sinusitis ( sign symptom last longer 28 day immediately prior Evaluation 1 ) Significant anatomical abnormality sinuses infection Condition necessitates use concomitant systemic antibiotic . Evidence uncontrolled clinically significant cardiovascular , pulmonary , metabolic , gastrointestinal , neurological , psychiatric endocrine disease , malignancy , abnormality ( disease study ) . Any underlying condition/disease , would likely interfere completion course study drug therapy followup . Known significant renal hepatic impairment ( disease ) . Subject take : systemic antibiotic within 2 week study drug administration longacting injectable antibiotic ( e.g. , penicillin G benzathine ) within 4 week study drug administration . Immunocompromised subject ( e.g. , neutropenic subject ) . Subjects know HIV infection . Treatment investigational drug within 4 week prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>